Floatz logo

Ligufalimab

Advanced Hepatocellular Carcinoma

University of Texas Southwestern Medical Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

520 Active assets in the Advanced Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Ligufalimab is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Locally Advanced Triple-negative Breast CancerDormant
CCC
Indicative ·
53 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →